Kalytera Is Set To Become The Next GW Pharmaceuticals After Groundbreaking Phase 2 Trial Results Seeking Alpha
Kalytera Therapeutics recently released Phase 2 clinical data with extremely positive results for its CBD product in the prevention of acute graft versus host d.